How melanomas bypass new therapy
Authors:
- 15 December 2010
- journal article
- Published by Springer Nature in Nature
- Vol. 468 (7326) , 902-903
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Gatekeeper Mutations Mediate Resistance to BRAF-Targeted TherapiesScience Translational Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in MelanomaCancer Research, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Mutations of the BRAF gene in human cancerNature, 2002